Zai Lab Limited (NASDAQ:ZLAB) is one of the 10 biotech stocks screaming a buy. On June 17, the company delivered positive ...

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders ...

The BBC content job to replace Charlotte Moore is heating up with Zai Bennett dropping out and Tom McDonald and David Brindley emerging.

On Tuesday, Cantor Fitzgerald analysts maintained an Overweight rating on Zai Lab (NASDAQ: ZLAB) stock, with a price target of $56.00, well above the current trading price of $31.19.According to ...

Presently, James Yan is Chief Operating Officer-Research & Development at Zai Lab Ltd. Dr. Yan is also Member of Chinese Society of Toxicology.

Median overall survival improved to 16.2 months with TTFields vs. 14.2 months for standard treatment. TTFields extended pain-free survival by 6.1 months, reaching a median of 15.2 months. Get ...

SHANGHAI & CAMBRIDGE, Mass., June 02, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating zocilurtatug pelitecan, or ZL-1310, the ...

BAAR, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating ...

Zai Lab Limited (NASDAQ:ZLAB) and NovoCure Limited (NASDAQ:NVCR) revealed landmark results from the Phase 3 PANOVA-3 trial at the 2025 ASCO Annual Meeting, marking the first therapy to show ...